EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score

Abstract Background and study aims  In borderline resectable/locally advanced pancreatic ductal adenocarcinoma (PDAC), stereotactic body radiation therapy (SBRT) is an emerging neoadjuvant treatment option. Endoscopic ultrasound (EUS)-guided insertion of fiducial markers being a prerequisite, our ai...

Full description

Saved in:
Bibliographic Details
Published in:Endoscopy International Open 2021-02, Vol.9 (2), p.E253-E257
Main Authors: Figueiredo, Mariana, Bouchart, Christelle, Moretti, Luigi, Mans, Laura, Engelholm, Jean-Luc, Bali, Maria-Antonietta, Van Laethem, Jean-Luc, Eisendrath, Pierre
Format: Article
Language:English
Subjects:
Original article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background and study aims  In borderline resectable/locally advanced pancreatic ductal adenocarcinoma (PDAC), stereotactic body radiation therapy (SBRT) is an emerging neoadjuvant treatment option. Endoscopic ultrasound (EUS)-guided insertion of fiducial markers being a prerequisite, our aim was to assess its feasibility and safety and also to evaluate its success, from both the endoscopist’s and radiotherapist’s perspectives. Patients and methods  We prospectively collected data concerning PDAC patients submitted to EUS-guided fiducial placement, from February 2018 to November 2019. Technical success was defined as at least one marker presumed inside the tumor. Quality success was assessed at pre-SBRT computed tomography, accordingly to the number of markers inside or 
ISSN:2364-3722
2196-9736
DOI:10.1055/a-1324-2892